



4<sup>TH</sup> INTERNATIONAL SYMPOSIUM

**ADVANCED  
OVARIAN CANCER:  
OPTIMAL THERAPY.  
UPDATE**

VALENCIA, SPAIN.  
FEBRUARY 28TH. 2003  
PALAU DE LA MÚSICA  
AUDITORIUM B

**PROGRAM**

**ADVANCED  
OVARIAN CANCER:  
OPTIMAL THERAPY.  
UPDATE**

**4<sup>TH</sup> INTERNATIONAL**

**SYMPOSIUM**

**DIRECTORS:**

JB VERMORKEN (ANTWERP, BELGIUM),  
A POVEDA (VALENCIA, SPAIN).

**SCIENTIFIC COMMITTEE:**

MA BOOKMAN (PHILADELPHIA, USA),  
A CERVANTES (VALENCIA, SPAIN),  
E GARCIA (VALENCIA, SPAIN),  
C MENDIOLA (MADRID, SPAIN),  
A POVEDA (VALENCIA, SPAIN),  
JB TRIMBOS (LEIDEN, THE NETHERLANDS),  
JB VERMORKEN (ANTWERP, BELGIUM),



08.30h

## WELCOME

09.00-11.00h

## 1<sup>st</sup> SESSION

CHAIRMEN: LOREM IPSUM DOLOR

- **Proteomic analysis for early detection of ovarian cancer: a realistic approach**  
ELISE C. KOHN (NCI, BETHESDA)
- **Update of conventional screening methods for ovarian cancer**  
IAN J JACOBS (LONDON, UNITED KINGDOM)
- **What have we learned from ICON-1 and ACTION?**  
SERGIO PECORELLI (BRESCIA, ITALY)  
NICOLETTA COLOMBO (MILAN, ITALY)

11.00h

## COFFE BREAK

11.30-13.30h

## 2<sup>nd</sup> SESSION

CHAIRMEN: LOREM IPSUM DOLOR

- **Gold standard for first-line chemotherapy in advanced ovarian cancer**
  - Long-term follow-up of GOG-111 and OV10  
MARTINE PICCART (BRUSSELS, BELGIUM)
  - Carboplatin/paclitaxel vs cisplatin/paclitaxel  
MICHAEL A BOOKMAN (PHILADELPHIA, USA)
  - Sequential single agent chemotherapy vs combination chemotherapy  
FRANCO M MUGGIA (NEW YORK, USA)
- **The potential role of neoadjuvant chemotherapy in advanced ovarian cancer**  
MARK BAEKELANDT ( OSLO, NORWAY)

11.00h

## LUNCH

15.00-17.30h

### 3<sup>rd</sup> SESSION

CHAIRMEN: LOREM IPSUM DOLOR

#### ■ The role of anthracyclines in ovarian cancer

- **Update of AGO GINECO study**  
ANDREAS DU BOIS (WIESBADEN, GERMANY)
- **Update of NSGO/EORTC/GEICO/NCIC study**  
GUNNAR KRISTENSEN (OSLO, NORWAY)
- **The role of anthracyclines in second-line treatment**  
JAN BAPTIST VERMORKEN (ANTWERP, BELGIUM)

#### ■ Is combination chemotherapy superior over single-agent chemotherapy in second-line treatment?

MIGUEL A IZQUIERDO (BARCELONA, SPAIN)

#### ■ Consolidation therapies revisited

- **Radiotherapy**  
B SORBE (ÖREBRO, SWEDEN)
- **IP chemotherapy**  
MARTINE PICCART (BRUSSELS, BELGIUM)

- **IV chemotherapy**  
MAURIE MARKMAN (CLEVELAND, USA)
- **Weekly paclitaxel**  
SERGIO PECORELLI (BRESCIA, ITALY)

17.30h

### TEA

18.00-19.15h

### 4<sup>th</sup> SESSION

CHAIRMEN: LOREM IPSUM DOLOR

#### ■ Cost-effectiveness studies in ovarian cancer

THOMAS D SZUCS (SWITZERLAND)

#### ■ Translation research in ovarian cancer: a must


THOMAS C HAMILTON (PHILADELPHIA, USA)

#### ■ Treatment policies for the next 10 years

ELISABETH EISENHAEUER (KINGSTON, CANADA)

#### ■ Remarks and Conclusion

ANDRES POVEDA (VALENCIA, SPAIN)



## **VENUE**

All sessions will take place at **PALAU DE LA MUSICA**.  
Paseo Alameda, 30. 46023 **VALENCIA**. Spain

## **SCIENTIFIC SECRETARIAT**

**Dr. ANDRÉS POVEDA.**

**Fundación IVO.**

**C/ Profesor Baguena, 8. 46009 VALENCIA. Spain**

**Phone: (34) 96 111 41 28**

**Fax: (34) 96 111 43 44**

**E-mail: [apoveda@ene.es](mailto:apoveda@ene.es)  
[apoveda@fivo.org](mailto:apoveda@fivo.org)**

## **ORGANIZING SECRETARIAT**

**(Registration and Accommodation).**

**ULTRAMAR EXPRESS, Congresos.**

**Gran Vía Marqués del Turia, 49 7L3. 46005 VALENCIA. SPAIN.**

**Phone (34) 96 352 81 61**

**E-mail: [bcaletrio@uex.es](mailto:bcaletrio@uex.es)**

## **CREDITS**

The symposium has been accredited by the European Society of Medical Oncology Educational Committee for its medical oncology recertification approval (ESMO/MORA) program with 7 credit/points category 1.

## **LANGUAGE**

The official language of the Symposium is English.  
Simultaneous translation into Spanish will be provided.

**ORGANIZED BY:**



**GEICO**  
(GRUPO ESPAÑOL DE  
INVESTIGACIÓN EN  
CÁNCER DE OVARIO)

**UNDER THE AUSPICES OF:**

**ESMO, SEOM, GEICO**